News
After FDA no, MSD/Daiichi post new data with lung cancer ADC
MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line tr
